ReviewWorld journal of gastrointestinal pharmacology and therapeutics2016
Eosinophilic gastroenteritis: Approach to diagnosis and management.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 126 citations in OpenAlex.
- Multifocal Giant Granular Cell Tumors of the Alimentary Canal With Concurrent Eosinophilic Gastrointestinal Disease.ACG case reports journal · 2026Article
- Diagnosis of small bowel obstruction secondary to eosinophilic enteritis using nasointestinal ileus tube and enteroscopy: a case report.BMC gastroenterology · 2026Article
- From esophagus to colon: A narrative review of eosinophilic gastrointestinal disorders.World journal of gastrointestinal pathophysiology · 2026Review
- Eosinophilic Colitis in an Adult Ethiopian Patient.Case reports in gastrointestinal medicine · 2026Article
- Article
- The Importance of Magnetic Resonance Enterography in Monitoring Inflammatory Bowel Disease: A Review of Clinical Significance and Current Challenges.Diagnostics (Basel, Switzerland) · 2025Review
- Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis.Clinical journal of gastroenterology · 2025Article
- Another Crohn's Disease Mimicker: A Case of Angiotensin-Converting Enzyme Inhibitor-Induced Intestinal Angioedema.ACG case reports journal · 2025Article
- The Unusual Clinical Presentation of Eosinophilic Gastroenteritis and Its Response to Mepolizumab: Two Case Reports.Cureus · 2024Article
- Cellular and molecular basis of proximal small intestine disorders.Nature reviews. Gastroenterology & hepatology · 2024Review
- Eosinophilic ascites and enteritis: a neglected case report from Vietnam.The Journal of international medical research · 2024Article
- Article
- Review
- Crohn's disease presenting with peripheral hypereosinophilia.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Successful Introduction of Benralizumab for Eosinophilic Ascites.Biomedicines · 2024Article
- Eosinophilic enteritis in a case of cystic fibrosis: an elusive diagnosis with an elementary cure.BMJ case reports · 2023Article
- Potential pitfalls in reporting non-neoplastic gastrointestinal mucosal biopsies.Histology and histopathology · 2023Review
- Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes.Digestive diseases and sciences · 2023Review
- Eosinophilic Gastroenteritis: Still a Diagnostic Challenge.GE Portuguese journal of gastroenterology · 2023Article
- Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases.International journal of molecular sciences · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic gastroenteritis (EGE) is a rare and benign inflammatory disorder that predominantly affects the stomach and the small intestine. The disease is divided into three subtypes (mucosal, muscular and serosal) according to klein's classification, and its manifestations are protean, depending on the involved intestinal segments and layers. Hence, accurate diagnosis of EGE poses a significant challenge to clinicians, with evidence of the following three criteria required: Suspicious clinical symptoms, histologic evidence of eosinophilic infiltration in the bowel and exclusion of other pathologies with similar findings. In this review, we designed and applied an algorithm to clarify the steps to follow for diagnosis of EGE in clinical practice. The management of EGE represents another area of debate. Prednisone remains the mainstay of treatment; however the disease is recognized as a chronic disorder and one that most frequently follows a relapsing course that requires maintenance therapy. Since prolonged steroid treatment carries of risk of serious adverse effects, other options with better safety profiles have been proposed; these include budesonide, dietary restrictions and steroid-sparing agents, such as leukotriene inhibitors, azathioprine, anti-histamines and mast-cell stabilizers. Single cases or small case series have been reported in the literature for all of these options, and we provide in this review a summary of these various therapeutic modalities, placing them within the context of our novel algorithm for EGE management according to disease severity upon presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.